D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP), a micro-cap company with a market value of $15.76 million, has relocated its principal executive office to Estero, Florida, according to an SEC filing released Wednesday.
The company’s Board of Directors approved the change on Tuesday, establishing the new headquarters at 23150 Fashion Drive, Suite 232, Estero, Florida 33928. This location will serve as the company’s principal executive office, principal place of business, and headquarters.
Prior to this move, Aspire Biopharma maintained its address in Humacao, Puerto Rico, at 194 Candelaro Drive, #233, postal code 00791.
The SEC filing was signed by Ernest Scheidemann, Chief Financial Officer of Aspire Biopharma Holdings.
Aspire Biopharma Holdings is listed on the Nasdaq Stock Market, trading under the symbol ASBP for its common stock and ASBPW for its warrants. The company is registered as an emerging growth company under SEC regulations.
The information in this article is based on an 8-K SEC filing submitted by the company.
In other recent news, Aspire Biopharma Holdings, Inc. has announced the start of production for its new pre-workout supplement, which utilizes the company’s patent-pending sublingual delivery technology. The supplement is designed to provide sustained energy and mental focus, featuring 100mg of caffeine and beta alanine to reduce lactic acid buildup during exercise. Aspire plans to conduct consumer and safety testing in the second quarter of 2025, with a launch expected within the same year at specialty nutritional product retailers. The company has also reached a settlement with Cobra Alternative Capital Strategies LLC and Blackstone (NYSE:BX) Capital Advisors, Inc. to amend terms of existing loan agreements, resolving previous notices of default and extending loan maturity dates to late 2025. As part of the settlement, Aspire will issue 625,000 shares of common stock to Blackstone, with lock-up restrictions on shares being lifted. Additionally, Aspire Biopharma has appointed Michael C. Howe as its new CEO, succeeding Kraig Higginson, who will remain as Executive Chairman. Howe’s leadership is anticipated to guide the company through significant milestones, including an important clinical trial and the anticipated launch of the pre-workout supplement. These developments are expected to provide Aspire with greater operational and financial flexibility moving forward.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.